TABLE 2.
Prior therapy in Chinese patients with relapsed/refractory B‐cell malignancies receiving zanubrutinib
| Part I | Part II | Total (N = 44) | ||
|---|---|---|---|---|
| 160 mg BID, (n = 11) | 320 mg QD, (n = 10) | 160 mg BID, (n = 23) | ||
| Number of prior lines of therapy | ||||
| Median | 4.0 | 3.0 | 3.0 | 3.0 |
| Min–max | 1–8 | 1–9 | 1–6 | 1–9 |
| Number of prior lines of therapy, n (%) | ||||
| 1 | 3 (27.3) | 1 (10.0) | 4 (17.4) | 8 (18.2) |
| 2 | 1 (9.1) | 2 (20.0) | 3 (13.0) | 6 (13.6) |
| 3 | 1 (9.1) | 4 (40.0) | 7 (30.4) | 12 (27.3) |
| 4 | 1 (9.1) | 1 (10.0) | 4 (17.4) | 6 (13.6) |
| 5 | 2 (18.2) | 1 (10.0) | 3 (13.0) | 6 (13.6) |
| ≥6 | 3 (27.3) | 1 (10.0) | 2 (8.7) | 6 (13.6) |
| Best response for last therapy, n (%) | ||||
| Complete response | 2 (18.2) | 0 (0.0) | 2 (8.7) | 4 (9.1) |
| Partial response | 2 (18.2) | 2 (20.0) | 6 (26.1) | 10 (22.7) |
| Stable disease | 2 (18.2) | 3 (30.0) | 3 (13.0) | 8 (18.2) |
| Progressive disease | 1 (9.1) | 3 (30.0) | 5 (21.7) | 9 (20.5) |
| Not applicable | 4 (36.4) | 2 (20.0) | 7 (30.4) | 13 (29.5) |
| Time from end of last therapy to study entry, months | ||||
| Median | 4.5 | 3.9 | 6.0 | 4.6 |
| Min–max | 0.0–51.4 | 0.0–38.2 | 0.0–87.4 | 0.0–87.4 |
Note: Zanubrutinib dose regimen is based on the first dose received. Percentages are based on number of patients who received ≥1 dose of zanubrutinib.
Abbreviations: BID, twice daily; min, minimum; max, maximum; QD, once daily.